TC Biopharm (Holdings) Plc (TCBP) एक सार्वजनिक रूप से कारोबार करने वाली कंपनी है में स्वास्थ्य सेवा क्षेत्र, संचालन करती है Biotechnology उद्योग. कंपनी का मुख्यालय है Motherwell, United Kingdom. वर्तमान CEO हैं Bryan Leland Kobel.
TCBP के पास है IPO तिथि 2022-02-11, 41 पूर्णकालिक कर्मचारी, पर सूचीबद्ध NASDAQ Capital Marke, बाजार पूंजीकरण $256.5K.
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.
